Clemidsogene lanparvovec
Gene therapy / editing
Also known as RGX-121
Evidence outlook · program status
On hold (2026-08), on a safety finding
FDA placed RGX-121 on clinical hold after asymptomatic spine MRI findings in five CAMPSIITE participants; REGENXBIO does not expect to resubmit the BLA in the near term (release of 2026-08-24). The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07236606 NCT07236606 · MPS II Registry: NCT07236606 | 3 | Efficacy of RGX-121 on Neurodevelopmental Function (as measured by the Bayley Scales of Infant and Toddler Development, 3rd Edition) (Month 24); Efficacy of RGX-121 on Neurodevelopmental Function (as measured by Kaufman Assessment Battery for Children, 2nd Edition) (Month 24); Long-term Safety of RGX-121 (Year 5) 2028-04-30 | In progress: results expected 30 Apr 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Iduronate-2-sulfatase (IDS) drugs
Tividenofusp alfa. Compare all 2 Iduronate-2-sulfatase (IDS) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Mucopolysaccharidosis Type II: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Clemidsogene Lanparvovec: this drug | Phase 3 | Gene therapy / editing | Iduronate-2-sulfatase (IDS) | not yet graded | No reviewed efficacy summary in this indication | |
| Tividenofusp Alfa (Avlayah) | Approved | Protein / enzyme therapeutic | Iduronate-2-sulfatase (IDS) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Development is on hold since 2026-08 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.
2028 (1)
April 2028 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent